[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ChromaDex, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100652420","a-12-week-randomized-placebo-controlled-quantitative-and-qualitative-evaluation-of-the-topical-efficacy-of-niacinamide-riboside-nr-on-signs-of-skin-aging-a-dose-response-comparison-in-women-ages-30-60-100652420",false,"NCT07774000","Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging","Randomized, Placebo-controlled Clinical Study for the Evaluation and the Comparison of the Dose-response Efficacy of 4 Cosmetic Investigational Products (3 Active, 1 Placebo; 1 Tested Investigational Product Per Subject), After Repeated Applications for 12 Weeks, Under Normal Conditions of Use, in Female Adult Subjects","NR-RADIANCE","Inclusion Criteria:\n\n* Open to all races provided they meet the inclusion and exclusion criteria below:\n* Gender: Female\n* Age: 30 to 60 years old\n* Phototype: I to VI\n* Subject presenting with fines lines\u002F wrinkles as Crow's feet, inclusion grade ≥ 3 and ≤ 6 on a 10-points scale.\n* Subject presenting with one or more visible signs of skin aging on face (example of signs of skin aging: wrinkles and fine lines, lack of firmness, lack of radiance, pigmented spots, dry and rough skin, visible pores, skin sagging).\n* Subject is not currently using NAD+ or another product containing Vitamin B3 (niacin, niacinamide, nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, myristyl nicotinate, etc.) administered topically, orally intravenously, or through any form of injection, as a part of their current routine or 4 weeks before starting study. The only permitted exception is the use of a multivitamin that contains niacin or nicotinamide. If this is the case, the product and dose of niacin or nicotinamide should be documented at screening and continuation of use of the product should be documented at each site visit.\n* Willingness to maintain current lifestyle, wellness and skin care routines (with the exception of the inclusion of the product requirements incorporated into the study protocol).\n\nExclusion Criteria:\n\n* Subject not providing consent;\n* Subject not complying with protocol requirements;\n* Subject of whom a health condition has changed since the inclusion visit in the I.E.C database, making the subject ineligible or places her at undue risk;\n* Active cancer diagnosis or diagnosis of cancer of any kind less than three years since remission, liver disease, kidney disease, or uncontrolled diabetes;\n* Pregnancy, actively breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study;\n* Subject having a medical treatment, recent vaccination or expecting to be vaccinated during the study, that makes the subject ineligible or places her at undue risk, in particular, medical treatment (either oral or topical) containing tretinoin or isotretinoin during the 3 months before the starting day of the study;\n* Subject having a background of intolerance or allergy to cosmetics, NAD+ or any vitamin B3 derivative, ingredients in the auxiliary products or to other substances that makes the subject ineligible or places her at undue risk;\n* Subject having visible traces of irritation or any other abnormality on the concerned area;\n* Subject having skin recently exposed to excessive sunlight (natural or artificial) within 4 weeks preceding the inclusion;\n* Subject having undergone surgery, chemical or physical treatment to the concerned area in the last 12 months (no injection during the last 6 months);\n* Subject having applied anti-wrinkle\u002Fanti-aging\u002Ffirming products on concerned area during the 4 weeks before the starting day of the study;\n* Subject having had any cosmetic procedures performed in the last six months (including Botox, peels, laser, etc.);\n* Subject having applied NAD+\u002FB-vitamin products on the concerned area during the 4 weeks before the starting day of the study;\n* Subject having modified his\u002Fher cosmetic habits (on the concerned area by the study) during the last 2 weeks, making her ineligible;\n* Subject having applied cosmetic or pharmaceutical products (other than their usual cleanser) to the areas of concern during the 96 hours before the starting day of the study and on the day of inclusion;\n* Subject having applied any cosmetic or pharmaceutical products (only water allowed) to the areas of concern the day of inclusion.",true,"FEMALE","30 Years","60 Years",{"count":22,"type":23},140,"ESTIMATED","INTERVENTIONAL",[26],"NA","Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+). Research published by Maussudi et al. 2012 demonstrated that skin NAD+ levels were negatively correlated with age in both males and females, and aged skin was also correlated to an increase in DNA damage. Therefore, it is proposed that supporting skin NAD+ with precursors such as NR may be a strategy to combat DNA damage that leads to undesirable signs of skin aging, thus supporting skin cell resilience. The use of NR as a dietary supplement has produced effective, efficient, and reproducible increases in NAD+ in humans. However, the role of topically applied NR for skin aging requires further investigation.\n\nThough not measuring NAD+ directly, this study will explore if topically applied NR reduces the signs of skin aging that may result from cellular NAD+ deficiency. It is hypothesized that the addition of NR to a general skin care regimen will result in healthier, more youthful appearing skin over 12 weeks.\n\nThe goal of this interventional clinical trial is to identify the most effective, tolerable, and efficient dose of NR for attenuating quantitative and qualitative indicators of facial skin aging in women ages 30-60. The three primary outcome measures are\n\n* Changes in skin biological age,\n* Quantitative reduction in fine lines and wrinkles near the eye, and\n* Changes in skin firmness and tightening.\n\nSecondary quantitative and qualitative outcomes include\n\n* Changes to pores, texture, redness, skin tone evenness, radiance, plumpness, and firmness on the global face.\n* Changes in skin moisture and skin barrier integrity, and\n* Participant perception of perceived efficacy, acceptability, and irritation.\n\nSkin imaging will also be employed in the study.\n\nParticipants will be randomized into one of four test product groups:\n\n* Placebo\n* 2.5% NR,\n* 5% NR, or\n* 10% NR.\n\nThe test product will be provided in a dry nanofiber sachet, and the percentage of NR is an estimate based on the final concentration of the applied material when mixed in serum.\n\nFollowing facial cleansing with the provided cleanser, study participants will prepare the test product (immediately before application) by dissolving a single sachet in the provided standardized gel serum. Following application, participants will apply the provided moisturizer and UV serum. Product application will occur twice daily for 84 days (12 weeks). In-clinic assessments will be performed at baseline and days 28, 56, and 84. Participants will also complete at home questionnaires on days 14 and 42. Adverse events and responses will be documented in participant diaries and immediately reported to the clinical research team.",[29,30,31,32],"Skin Aging on Face","Skin Care Dermocosmetics","Skin Care","Fine Lines and Wrinkles",[34,35,36,37,38,39,40],"nicotinamide riboside","niacinamide riboside","nicotinamide adenine dinucleotide","skin aging","skin aging clock","topical","skin care","RECRUITING","2026-08-19",{"date":44,"type":45},"2026-08-21","ACTUAL",{"date":47,"type":45},"2026-08-17",{"date":49,"type":23},"2027-03-31",{"name":51,"class":52},"ChromaDex, Inc.","INDUSTRY",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100612286","phase-1-randomized-open-label-safety-study-of-subcutaneous-and-intramuscular-injections-of-niagen-plus-100612286","NCT07251608","Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus","Randomized, Open-Label, Safety Pilot Study of Multiple Subcutaneous and Intramuscular Injections of Niagen® Plus","Inclusion Criteria:\n\n* Generally healthy adults, aged 18+\n* Demonstrated baseline fatigue as determined by a below average score from the FAS (threshold prespecified in SAP).\n* NAD+ or NAD+ precursor injection naïve (including intravenous, intramuscular, subcutaneous, or other injection route) (i.e., 8 weeks abstinent)\n* Non-anemic\n* Willingness to adhere to lifestyle considerations and study procedures.\n* Ability to read English, and provide written informed consent.\n* Willingness to self-administer the study material, via subcutaneous injection for 90 days (days 10-100 of the study), and complete finger prick blood collections.\n\nExclusion Criteria:\n\n* One or more uncontrolled chronic illness including but not limited to diabetes, cardiovascular disease, liver, disease, kidney disease, or any form of cancer. An uncontrolled chronic illness, in this case, is defined as any changes to medication or other treatment modalities in the last 90 Days.\n* More than one chronic disease diagnosis under active treatment.\n* Any chronic disease, as determined by the primary investigator, that increases risk or confounds safety.\n* Any acute illness within 14 Days prior to Visit 1 (Day 1).\n* Cancer diagnosis within the last 5 years\n* Anemia (as defined by hemoglobin levels below 100 g\u002FL, and other blood measures)\n* Current pregnancy or lactation; unwilling to use effective contraception if of childbearing potential.\n* Use of any NAD+ supplement, NAD+ precursor, or vitamin B3 product, orally, nasally, by patch, or injection within the last 60 Days. NAD+ precursors and related compounds include niacin (NA), nicotinamide (NAM), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), NAD+, NADH, NAD+3, inositol hexanicotinate, apigenin; etc. The exception is the use of a daily oral multivitamin, that may contain vitamin B3 (niacin\u002Fnicotinamide). Such use will need to be documented.\n* Hypersensitivity or allergy to NR, niacin, other forms of vitamin B3\u002FNAD+ precursors, bacteriostatic water\n* Significant aversion to needles or finger pricks.\n* Participation in another clinical intervention study, 90 Days (or 5 half-lives of the intervention, whichever is longer) prior to Visit 1 (Day 1).\n* Any other condition rendering the participant unsuitable per investigator.\n* Excessive daily use of alcohol, defined as 4 or more drinks on one occasion, or illicit drug use which would prevent adherence to the protocol as determined by the investigator.","ALL","18 Years",{"count":64,"type":23},40,[66],"PHASE1","The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood. Niagen®Plus will be given either by subcutaneous (under the skin) or intramuscular (into the muscle) injection at two dose levels (50 mg or 100 mg).\n\nThe main questions this study aims to answer are:\n\nIs Niagen®Plus safe and well-tolerated when given by injection several times over 100 days?\n\nHow do NAD+ levels in blood change after repeated doses of Niagen®Plus?\n\nWhat are participants' and clinicians' experiences with the injections?\n\nResearchers will also look at changes in fatigue, sleep, quality of life, inflammation markers, mitochondrial efficiency, and perceived skin appearance.\n\nParticipants will:\n\nReceive three injections in clinic on Days 1-3, followed by a Day 10 follow-up visit\n\nSelf-inject Niagen®Plus at home three times per week from Days 10-100\n\nReturn to the clinic on Days 40 and 100 for safety and laboratory testing\n\nComplete short surveys about fatigue, sleep, and overall well-being throughout the study\n\nThe study will include 40 generally healthy adults and will last about 100 days per participant.",[69,70],"Healthy Volunteer","Fatigue","2025-11-19",{"date":73,"type":45},"2025-11-26",{"date":75,"type":45},"2025-10-01",{"date":77,"type":23},"2026-02-15",{"name":51,"class":52},""]